Understanding Trauma Nightmares Using In-Home Measurement
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03974503|
Recruitment Status : Recruiting
First Posted : June 5, 2019
Last Update Posted : May 7, 2020
|Condition or disease||Intervention/treatment||Phase|
|Nightmares Stress Disorders, Post-Traumatic Actigraphy Respiratory Sinus Arrhythmia Veterans||Behavioral: Exposure, Relaxation, and Rescripting Therapy Behavioral: Sleep and Nightmare Management||Not Applicable|
There is a critical need for continued research to better understand trauma-related nightmares with the goal of developing personalized treatment plans. Limitations of current assessment procedures present a significant barrier to improved care. In-laboratory sleep studies rarely capture nightmares and cannot assess change over time, reducing the knowledge of phenotypic markers of nightmares to guide treatment. Therefore, there is a need to assess sleep over multiple nights in the home environment, where nightmares occur. This study aims to significantly enrich knowledge about trauma-related nightmares by using a zero-burden, multi-night, objective sleep measurement method within Veterans' usual sleeping environment prior to and during an evidence-based cognitive-behavioral intervention for nightmares. This study has two primary aims: 1) to identify, with greater precision than previously possible, objective features of sleep associated with trauma-related nightmare occurrences; and 2) to use the treatment for nightmares as interventional probes to determine whether and how changes in sleep physiological parameters identified in Aim 1 covary with changes in subjective nightmare frequency and severity.
The study will include 80 trauma-exposed Veterans reporting with trauma-related nightmares. Eligible participants will monitor their sleep for a week using a multi-night mattress actigraphy implemented in their home. Mattress actigraphy, which measures movements using accelerometers embedded in a mattress topper, employs no body surface sensors. Therefore, this system represents a truly zero-burden method for obtaining intensive longitudinal sleep measurement. During the week of sleep monitoring, participants also will complete one-night of polysomnography (PSG) sleep assessment to calibrate the actigraphic sleep efficiency and to identify untreated sleep apnea. These methods will be used to investigate candidate physiological parameters associated with trauma-related nightmares. After establishing the levels of these candidate markers, this project will assess the impact of a cognitive-behavioral treatment, Exposure, Relaxation, and Rescripting Therapy (ERRT), on the subset of markers which can be measured continuously over the course of the treatment. Participants will be randomized to five weeks of active treatment (ERRT; n = 40) or to five weeks of the comparison treatment (sleep and nightmare management; n = 40). Throughout the course of treatment, participants will continue to sleep while monitored by the mattress actigraphy system. Upon completion of treatment, a post-treatment and follow-up assessment will assess subjective symptom change. Results from this study will provide important information to facilitate increased understanding of the phenomenology, pathophysiology, and treatment of nightmares in trauma-exposed Veterans.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||96 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Participants will be randomly assigned to one of two cognitive-behavioral treatments for sleep and nightmares.|
|Masking:||Single (Outcomes Assessor)|
|Masking Description:||Assessors at the post-treatment and follow-up assessment will not be aware of what treatment the participants received.|
|Official Title:||Characterization of Sleep With Trauma Nightmares Using Ambulatory Sleep Measurement|
|Actual Study Start Date :||December 2, 2019|
|Estimated Primary Completion Date :||January 2, 2024|
|Estimated Study Completion Date :||July 1, 2024|
Experimental: Exposure, Relaxation, and Rescripting Therapy (ERRT)
Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately one hour per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, sleep behavior modification, Progressive Muscle Relaxation, diaphragmatic breathing, exposure to the trauma-nightmare, rescription, and treatment maintenance planning.
Behavioral: Exposure, Relaxation, and Rescripting Therapy
ERRT is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in trauma-exposed adults.
Other Name: ERRT
Active Comparator: Sleep and Nightmare Management
This treatment protocol has amounts of therapist contact, handouts, and homework between sessions equivalent to those in ERRT. The protocol contains psychoeducation about sleep disturbances and trauma-related nightmares, including their distressing nature, chronicity, and impact on sleep and daytime functioning. Additionally, basic sleep behavior modification are presented. No nightmare content or rescripting will be explicitly discussed, and the diaphragmatic breathing techniques will be omitted from this protocol.
Behavioral: Sleep and Nightmare Management
This is a manualized protocol developed to be of similar length but exclude the active components of standard ERRT.
- Change in Actigraphy-derived sleep efficiency (SE) [ Time Frame: Nightly up to 7 weeks (Baseline through 1-week post treatment assessment) ]Mattress actigraphy will be continuously recorded during the study period. Sleep efficiency is defined as the ratio of the aggregate duration of quiescent sleep periods divided by the duration of the total in bed period. Lower sleep efficiency indicates worse sleep.
- Change in Actigraphy-derived respiratory sinus arrhythmia (RSA) [ Time Frame: Nightly (Baseline until 1-week post treatment assessment; 7 weeks) ]Mattress actigraphy will be continuously recorded during the study period. RSA is the high frequency powers of heart period variability (0.15-0.4 Hz). Lower RSA indicates more cardiac vagal withdrawal.
- Change in Nightmare Frequency [ Time Frame: Baseline past week; Nightly during baseline; 1-week post-treatment; 3-month follow-up treatment period ]This fill-in-the-blank variable assesses the number of nightmares experienced in the past week (range = 0 - X nightmares) at each assessment (baseline, one week following treatment, and three months following treatment). Nightly reports will be collected from daily sleep diaries and pushes to event markers during the night.
- Change in PTSD Symptom Severity [ Time Frame: Baseline, 1-week post-treatment, 3-month follow-up ]Change in PTSD Symptoms will be assessed using the Clinician-Administered PTSD Scale DSM 5 (CAPS-5) and the self-report PTSD Symptom Checklist. The items on the CAPS-5 are on a 5-point scale (0 - 4), (possible range: 0-80). A symptom is considered present if the severity is rated 2 or higher. Total scores are comprised of four factors (reexperiencing, avoidance, cognitive/emotional and hyperarousal)
- Change in Nightmare Severity [ Time Frame: Baseline; Nightly during baseline; 1-week post-treatment; 3-month follow-up treatment period ]The variable from the Trauma-Related Nightmare Survey assesses the severity of the nightmares experienced in the past week (range = 0 - 4) at each assessment (baseline, one week following treatment, and three months following treatment). Nightly reports of nightmare severity will be collected from daily sleep diaries. Higher scores indicate greater nightmare-related severity.
- Home-based overnight polysomnography [ Time Frame: Baseline ]Nox A1 portable polysomnography system (Nox Medical, Reykjavik, Iceland) used to record sleep stage measures and patterns of arousals, to calibrate sleep efficiency derived from the mattress system, and to detect sleep apnea.
- Change in Global Sleep Quality [ Time Frame: Baseline, 1-week post-treatment, 3-month follow-up ]
Change in sleep Quality will be assessed using the Pittsburgh Sleep Quality Index, a 19-item self-report measure assessing qualities and problems associated with sleep in the past month. A global sleep quality score is obtained by summing seven component scores. Higher scores reflect poorer sleep quality. The global score ranges from 0 to 21, with a cut-off score of 5 as distinguishing "good" sleepers from "poor" sleepers.
The addendum is used in conjunction with the PSQI for use with trauma-exposed participants and assesses the presence of seven trauma-related sleep disturbances.
- Change in self-report depression symptoms [ Time Frame: Baseline, 1-week post-treatment, 3-month follow-up ]The patient health questionnaire (PHQ-9), is a 9-item self-report instrument used to assess depression severity. Items are scored 0 to 3, with the total score being the sum of the 9 items. Higher scores indicate greater depression severity, with a score of 10 or greater considered major depression, and scores of 20 or more is severe major depression.
- Change in Nightmare Effects [ Time Frame: Baseline, 1-week post-treatment, 3-month follow-up ]Change in the impact of nightmares will be assessed using the change in Nightmare Effects Survey, an 11 item Likert-type questionnaire designed to assess the impact of nightmares on 11 areas of life including work, social, and leisure activities. Total scores range from 0 to 44, with higher scores indicating greater level of nightmare-related impairment.
- Change in Fear of Sleep [ Time Frame: Baseline, 1-week post-treatment, 3-month follow-up ]Change in fear of sleep will be assessed using the Fear of Sleep Inventory, a 23-item self-report measure that assesses trauma-related thoughts and activities associated with sleep and the occurrence of traumas associated with the bedroom or sleep. Total scores range from 0 to 92, with higher scores indicating greater fear of sleep.
- Change in suicidal ideation [ Time Frame: Baseline, 1-week post-treatment, 3-month follow-up ]Change in suicidal ideation will be assessed using the Depressive Symptom Index: Suicidality Subscale (DSI-SS). The four items of the DSI-SS are scored on a 0-3 scale, with total possible sum scores ranging from 0-12; higher scores indicate greater severity of suicidal ideation.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03974503
|Contact: Katherine E Miller, PhD||(215) 823-5800 ext 2105||Katherine.Miller13@va.gov|
|United States, Pennsylvania|
|Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Katherine E Miller, PhD (215) 823-5800 ext 2105 Katherine.Miller13@va.gov|
|Principal Investigator: Katherine Elizabeth Miller, PhD|
|Principal Investigator:||Katherine Elizabeth Miller, PhD||Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA|